European listed biotech landscape: 2021 review and outlook for 2022

Table of Content 1. 2021, a year to forget for the sector, or to learn from? 2. Status on COVID-19 3. Key Events in 2021 (Morphosys transformative deal, main approvals, Galapagos, Oncopeptides) 4. 2021 Highlights (Approval rates, IPOs & new listings, financing) 5. 2021 Lowlights (Clinical trial success rates, performances of commercial launches, Sweden, deals)[…]

European listed biotech landscape: 2020 review and outlook for 2021

Table of Content 1. Intro on COVID-19 2. How the European listed biotech companies try to help for vaccines and therapies against COVID-19 3. 2020 Highlights (financing, Genmab, Morphosys, approvals, “Billion Euro Biotech Club”, valuations) 4. 2020 Lowlights (Galapagos, Genfit, DBV, IPOs, AIM) 5. 2020 Deals and M&As 6. 2020 Stock and Index Performances 7.[…]

Summary of the COVID-19 vaccine supply agreements for Europe (incl. the UK & Switzerland), the US, Japan, Canada, Australia (28/02/2021 update)

Change log: * The updates from 08/11/2020 and later include additional data in the tables since the first publication on 25/08/2020, and only in the tables. * Calculation errors were corrected on 20/11/2020 and on 12/12/2020 (errors in aggregate nb of doses and avg nb of course/inh. for the US data). * Major update for[…]

The European listed biotech companies with COVID-19 programs: status & follow-up (updated 13/01/2021)

In the context of the COVID-19/SARS-Cov-2 pandemic, many biopharma companies throughout the world try to bring therapeutic options, on top of the topic of testing, which will not be focused on here. Some European listed companies have joined this international effort over the past weeks, and especially since the month of March. Vaccine development has[…]

European listed biotech companies: stock performance tracking after the coronavirus outbreak (updated)

The markets have been very volatile lately, and the main indices have known historical sessions in terns or performances on last Monday (09/03/2020), and even worse on last Thursday (12/03/2020, a real “Black Thursday” of the 21st century). That day, the European markets saw either their largest falls ever, either their worst performances since 19/10/1987[…]